HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.